Benefit/risk of leflunomide in rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 22, Issue 5 SUPPL. 35, 2004, Pages

  Kremer, Joel M ^a   Cannon, Grant W ^b  

^a ALBANY MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

Benefit risk; Leflunomide; Rheumatoid arthritis

Indexed keywords

ALANINE AMINOTRANSFERASE; CORTICOSTEROID DERIVATIVE; DRUG METABOLITE; ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PLACEBO; SALAZOSULFAPYRIDINE;

AGRANULOCYTOSIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ARTICLE; BRONCHITIS; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DIARRHEA; DRUG ALCOHOL INTERACTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FATALITY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; INTERSTITIAL PNEUMONIA; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LIVER DYSFUNCTION; LIVER TOXICITY; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MAINTENANCE DRUG DOSE; MYELOMA; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; OPPORTUNISTIC INFECTION; PARESTHESIA; PNEUMONIA; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; STRUCTURE ACTIVITY RELATION; UPPER RESPIRATORY TRACT INFECTION; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; DISEASE SURVEILLANCE; DRUG QUALITY; DRUG TOLERANCE; LEUKOPENIA; LIVER BIOPSY; LIVER INJURY; MORBIDITY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PYRIMIDINE METABOLISM; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SEPSIS; SIDE EFFECT;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; HUMANS; ISOXAZOLES; RISK ASSESSMENT;

EID: 4944231974     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. BARTLETT RR, SCHLEYERBACH R: Immunopharmacological profile of a novel isoxazol derivative, HWA 486, with potential antirheumatic activity. I. Disease modifying action on adjuvant arthritis of the rat. Int J Immunopharmacol 1985; 7: 7-18.
2. KUCHLE CC, THOENES GH, LANGER KH et al.: Prevention of kidney and skin graft rejection in rats by leflunomide, a new immunomodulating agent. Transplant Proc 1991; 23: 1083-6.
3. McCHESNEY LP, XIAO F, SANKARY HN et al.: An evaluation of leflunomide in the canine renal transplantation model. Transplantation 1994; 57: 1717-22.
4. MacDONALD AS, SABR K, MacAULEY MA et al.: Effects of leflunomide and cyclosporine on aortic allograft chronic rejection in the rat. Transplant Proc 1994; 26: 3244-5.
5. YUH DD, GANDY KL, MORRIS RE et al.: Leflunomide prolongs pulmonary allograft and xenograft survival. J Heart Lung Transplant 1995; 14: 1136-44.
6. BARTLETT RR, DIMITRIJEVIC M, MATTAR T et al.: Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection. Agents Actions 1991; 32: 10-21.
7. BARTLETT RR, ANAGNOSTOPULOS H, ZIELINSKI T et al.: Effects of leflunomide on immune responses and models of inflammation. Semin Immunopathol 1993; 14: 381-94.
8. THOSS K, HENZGEN S, PETROW PK et al.: Immunomodulution of rat antigen-induced arthritis by leflunomide alone and in combination with cyclosporin A. Inflamm Res 1996; 45: 103-7.
9. HAMBLETON P, McMAHON S: Drug actions on delayed-type hypersensitivity in rats with developing and established adjuvant arthritis. Agents Actions 1990; 29: 328-32.
10. PASTERNAK RD, WADOPIAN NS, WRIGHT RN et al.: Disease modifying activity of HWA 486 in rat adjuvant-induced arthritis. Agents Actions 1987; 21: 241-3.
11. GLANT TT, MIKECZ K, BARTLETT RR et al.: Immunomodulation of proteoglycan-induced progressive polyarthritis by leflunomide. Immunopharmacology 1992; 23: 105-16.
12. GLANT TT, MIKECZ K, BRENNAN F et al.: Suppression of autoimmune responses and inflammatory events by leflunomide in an animal model for rheumatoid arthritis. Agents Actions 1994; 41: C267-C270.
13. THOENES GH, SITTER T, LANGER KH et al.: Leflunomide (HWA 486) inhibits experimental autoimmune tubulointerstitial nephritis in rats. Int J Immunopharmacol 1989; 11: 921-9.
14. VIDIC-DANKOVIC B, KOSEC D, DAMJANOVIC M et al.: Leflunomide prevents the development of experimentally induced myasthenia gravis. Int J Immunopharmacol 1995; 17: 273-81.
15. Popovic S, BARTLETT RR: Disease modifying activity of HWA 486 on the development of SLE in MRL/1-mice. Agents Actions 1986; 19: 313-4.
16. POPOVIC S, BARTLETT RR: The use of the murine chronic graft vs host (CGVH) disease, a model for systemic lupus erythematosus (SLE), for drug discovery. Agents Actions 1987; 21: 284-6.
17. MLADENOVIC V, DOMLJAN Z, ROZMA B et al.: Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis. Results of a randomized, placebo-controlled, phase II study. Arthritis Rheum 1995; 38: 1595-603.
18. STRAND V, COHEN S, SCHIFF M et al.: Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med 1999; 159: 2542-50.
19. COHEN S, CANNON GW, SCHIFF M et al.: Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Arthritis Rheum 2001; 44: 1984-1992.
20. KREMER JM, ALARCON GS, LIGHTFOOT RW et al.: Methotrexate for rheumatoid arthritis: suggested guidelines for monitoring liver toxicity. Arthritis Rheum 1994; 37: 316-28.
21. SHARP JT, STRAND V, LEUNG H, HURLEY F, LOEW-FRIEDRICH I: Treatment with leflunomide shows radiographic progression of rheumatoid arthritis. Results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 1999; 43: 1345-51.
22. REECE RJ, KRAAN MC, RADJENOVIC A et al.: Comparative assessment of leflunomide and methotrexate for the treatment of rheumatoid arthritis: a double-blind, randomized, multicenter trial. Lancet 1999; 353: 259-66.
23. KREMER JM: Towards a better understanding of methotrexate. Arthritis Rheum 2004; 50: 1370-82.
24. WEINBLATT ME, KREMER JM, COBLN JS et al.: Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 1999; 37: 316-28.
25. KREMER JM, GENOVESE MC, CANNON GW et al.: Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized comparison of efficacy, safety, and tolerability compared to methotrexate alone. Ann Intern Med 2002: 137; 726-33.
26. KREMER JM, GENOVESE M, CANNON GW et al.: Combination of leflunomide and methotrexate in patients with active rheumatoid arthritis failing MTX inonotherapy: an open-label extension study. J Rheumatol 2004, in press.
27. KREMER JM, FURST DE, WEINBLATT ME, BLOTNER SD: Significant changes in serum AST across hepatic histological biopsy grades: Prospective analysis of 3 cohorts receiving methotrexate therapy for rheumatoid arthritis. J Rheumatol 1996; 23: 459-61.
28. KREMER JM, KAYE GI, KAYE NW, ISHAK KG, AXIOTIS CA: Light and electron micorscopic analysis of sequential liver biopsy samples from patients with rheumatoid arthritis receiving long term methotrexate therapy: follow-up over prolonged treatment intervals and correlation with clinical and laboratory variables. Arthritis Rheum 1995: 38; 1194-203.
29. CANNON GW, KREMER JM: Leflunomide. Rheum Dis Clin North Am 2004; 295-310.
30. ISOMAKI H, HAKULINEN T, JOUTSENLAHTI U: Excess risk of lymphomas, leukemia and meloma in patients with rheumatoid arthritis. J Chronic Dis 1978; 31: 691-6.
31. STARKEBAUM G: Rheumatoid arthritis, methotrexate, and lymphoma: risk substitution, or cat and mouse with Epstein-Barr virus ? J Rheumatol 2001; 28: 2573-5.
32. KREMER JM, ALARCON GS, WEINBLATT ME et al.: Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum 1997: 40: 1829-37.
33. KREMER JM, HAMILTON RA: The effects of nonsteroidal anti-inflammatory drugs on methotrexate pharmacokinetics: impairment of renal clearance of MTX at weekly maintenance doses but not at 7.5 mg. J Rheumatol 1995; 22: 2072-7.